Late prasugrel benefit in STEMI patients?

American Journal of Therapeutics

Volumn 16, Issue 6, 2009, Pages 469-470

  Serebruany, Victor L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical outcomes; Clopidogrel; Myocardial infarction; Prasugrel

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PRASUGREL;

BLOOD CLOT LYSIS; CANCER RISK; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; LONG TERM CARE; MORTALITY; PRIORITY JOURNAL; SEX DIFFERENCE; SHORT SURVEY; ST SEGMENT ELEVATION; TREATMENT OUTCOME;

HUMANS; MYOCARDIAL INFARCTION; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEX FACTORS; THIOPHENES; TICLOPIDINE;

EID: 74549142924     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181a8cd68     Document Type: Short Survey

References (3)

1. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2007;357:2001-2015. (Pubitemid 350106708)
2. Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-segment elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomized controlled trial. Lancet. 2009;373:723-731.
3. Prasugrel Secondary Review. Available for download at http://www.fda.gov/ohrms/dockets/ac/09/briefing/ 2009-4412b1-00-FDA.htm.